ATM and cancer: Since in cancer cells Onc-p53 mutants have a long half-life, which allows their accumulation (48, 49), the contribution of Onc-p53-induced ATM signaling (Fig. 2D) to the half-life of Onc-p53 was investigated using cycloheximide chase assay (50).